Camille L. Bedrosian
Chief Medical Officer at Amylyx Pharmaceuticals; Director at Rhythm Pharmaceuticals; EVP and Chief Medical Officer at Ultragenyx Pharmaceutical. Based in Cambridge, Massachusetts.
- Rank
- 9589th of 14,452
- Companies held
- 3
- Largest holding
- AMLX, 81.8% of total
- Latest SEC filing
- Sep 10, 2026
What the $8.9M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals AMLX Common Stock | Directly | 278,064 | $26.20 | $7.3M | 81.8% | Form 4, Sep 10, 2026 |
| Rhythm Pharmaceuticals RYTM Common Stock | Directly | 7,000 | $116.80 | $818K | 9.2% | Form 4, Jun 18, 2025 |
| Ultragenyx Pharmaceutical RARE Common Stock | Directly | 46,720 | $17.22 | $805K | 9.0% | Form 4, Mar 1, 2023 |
Share counts are the amounts Camille L. Bedrosian reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 9586 | Gregory Wong CFO, QuinStreet. Foster City, CA | $8.9M |
| 9587 | Bruce P. Nolop Director, Marsh & McLennan Companies. New York, NY | $8.9M |
| 9588 | Adele Louise Pentland SVP General Counsel, Secretary, Roku. San Jose, CA | $8.9M |
| 9589 | Camille L. Bedrosian Chief Medical Officer, Amylyx Pharmaceuticals. Cambridge, MA | $8.9M |
| 9590 | Bruce K. Baude Chief Ops & Tech Officer, CNO Financial Group. Carmel, IN | $8.9M |
| 9591 | Samantha Sacks Gallagher General Counsel and EVP, VICI Properties. New York, NY | $8.9M |
| 9592 | Dov S. Zakheim Director, TTM Technologies. Santa Ana, CA | $8.9M |
Other Amylyx Pharmaceuticals insiders
All AMLX insiders- Joshua B. Cohen$92.0MCo-Chief Executive Officer. #1598 overall
- Justin B. Klee$92.0MCo-Chief Executive Officer. #1599 overall
- George M. Milne Jr.$20.5MDirector. #4876 overall
- James M. Frates$10.1MChief Financial Officer. #8734 overall
- Margaret Olinger$7.2MChief Commercial Officer. #11150 overall
- Patrick D. Yeramian$5.4MChief Medical Officer. #13745 overall
Questions
How much stock does Camille L. Bedrosian own?
Camille L. Bedrosian holds $8,907,395 in listed stock based on SEC filings and current prices, mostly Amylyx Pharmaceuticals (AMLX). That ranks 9589th on the Stock Rich List.
Is this Camille L. Bedrosian's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Camille L. Bedrosian last buy or sell stock?
The most recent open-market trade on file is a sale of 7,947 AMLX shares on Sep 10, 2026 at $32.21.